Abstract
Targeting tumor microenvironment and angiogenesis is a novel therapeutic strategy in hematological malignancies. The antiangiogenic effects of chemotherapeutic agents can be optimized when administered metronomically, by providing low doses of chemotherapeutic drugs on a continuous schedule without extended drug-free intervals. Metronomic chemotherapy preferentially targets endothelial cells of the growing tumor neovasculature instead of tumor cells themselves and therefore can be particularly effective against multidrug-resistant tumors. Metronomic therapy may further enhance immune response by modulating antitumor NK/T-cell functions. The past decade saw an increasing appreciation of the pathogenic roles that tumor angiogenesis plays in hematological malignancies including leukemias, lymphomas, and multiple myeloma. Experimentation with a variety of antiangiogenesis modalities has shown encouraging efficacy with metronomic chemotherapy in these disease categories, with generally low toxicity and cost. With the growing availability of the target-specific biological agents, some of which are specific for antiangiogenesis, it is conceivable that metronomic chemotherapy, either alone or in combination with biologics, has therapeutic potential in frontline and maintenance setting, in addition to its traditional role of salvage option for relapsed diseases in hematological malignancies.
Financial Disclosure
J. R. has received research support from Celgene, Seattle Genetics, and Millennium.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436
Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967–974
Shaked Y, Bertolini F, Emmenegger U, Lee CR, Kerbel RS (2006) On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. J Clin Oncol 24(24):4040; author reply 4040–4041
Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS (2005) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65(16):7045–7051
Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886
Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62(23):6938–6943
Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100(22):12917–12922
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15):4342–4346
Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106(9):3058–3061
Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72(14):3439–3444
Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7):2862–2868
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56(5):641–648
Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels J-PH, Bieler JG, Emens LA, Reilly RT, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201(10):1591–1602
Wan S, Pestka S, Jubin RG, Lyu YL, Tsai Y-C, Liu LF (2012) Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One 7(3):e32542
Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82(1):40–50
Sharabi A, Ghera NH (2010) Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. Adv Cancer Res 107:1–37
Heissig B, Ohki Y, Sato Y, Rafii S, Werb Z, Hattori K (2005) A role for niches in hematopoietic cell development. Hematology 10(3):247–253
Hatfield K, Øyan AM, Ersvaer E, Kalland K-H, Lassalle P, Gjertsen BT, Bruserud Ø (2009) Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 144(1):53–68
Kruizinga RC, de Jonge HJM, Kampen KR, Walenkamp AME, de Bont ESJM (2011) Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 56(2):294–297
Mourah S, Porcher R, Lescaille G, Rousselot P, Podgorniak M-P, Labarchède G, Naimi B, Medioni J, Dombret H, Calvo F (2009) Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia, Int J Biol Markers 24(1):22–31
Kuzu I, Beksac M, Arat M, Celebi H, Elhan AH, Erekul S (2004) Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma 45(6):1185–1190
Trujillo A, McGee C, Cogle CR (2012) Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012:128608
Hatfield KJ, Evensen L, Reikvam H, Lorens JB, Bruserud Ø (2012) Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. Eur J Haematol 89(6):478–490
Veiga JP, Costa LF, Sallan SE, Nadler LM, Cardoso AA (2006) Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol 34(5):610–621
Schaefer C, Krause M, Fuhrhop I, Schroeder M, Algenstaedt P, Fiedler W, Rüther W, Hansen-Algenstaedt N (2008) Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia 22(1):59–65
Wang L, Shi W-Y, Yang F, Tang W, Gapihan G, Varna M, Shen Z-X, Chen S-J, Leboeuf C, Janin A, Zhao W-L (2011) Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Haematologica 96(6):927–931
Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S (2003) Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17(3):604–611
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S (2001) Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 98(19):10857–10862
He R, Liu B, Yang C, Yang RC, Tobelem G, Han ZC (2003) Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence. Cancer Gene Ther 10(12):879–886
Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR (2010) Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 116(9):1539–1547
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150(3):815–821
Wierzbowska A, Robak T, Krawczyńska A, Pluta A, Wrzesień-Kuś A, Cebula B, Robak E, Smolewski P (2008) Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 87(2):97–106
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835–3849
Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br J Cancer 79(5–6):965–970
Arias V, Soares FA (2000) Vascular density (tumor angiogenesis) in non-Hodgkin’s lymphomas and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 40(1–2):157–166
Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56(1–2):45–53
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159–2169
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink H-K, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323
Taskinen M, Karjalainen-Lindsberg M-L, Nyman H, Eerola L-M, Leppä S (2007) A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 13(19):5784–5789
Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S (2006) Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin’s lymphoma. Clin Cancer Res 12(19):5622–5631
Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA (2013) Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 121(26):5192–5202
Ribatti D, Vacca A (2008) The role of microenvironment in tumor angiogenesis. Genes Nutr 3(1):29–34
Podar K, Chauhan D, Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23(1):10–24
Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, Scavelli C, Nico B, Gernone A, Battelli F, Tabilio A, Guidolin D, Petrucci MT, Ribatti D, Dammacco F (2003) Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102(9):3340–3348
Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93(9):3064–3073
Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S (2011) Angiogenesis and multiple myeloma. Cancer Microenviron 4(3):325–337
Bhutani M, Turkbey B, Tan E, Kemp TJ, Pinto LA, Berg AR, Korde N, Minter AR, Weiss BM, Mena E, Lindenberg L, Aras O, Purdue MP, Hofmann JN, Steinberg SM, Calvo KR, Choyke PL, Maric I, Kurdziel K, Landgren O (2014) Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia 28(2):413–416
Medinger M, Fischer N, Tzankov A (2010) Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol 2010:729725
Bolkun L, Lemancewicz D, Sobolewski K, Mantur M, Semeniuk J, Kulczynska A, Kloczko J, Dzieciol J (2013) The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment. Adv Med Sci 58(1):118–125
Kopp H-G, Avecilla ST, Hooper AT, Rafii S (2005) The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20:349–356
Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, Dammacco F (2004) CXCR3-binding chemokines in multiple myeloma. Cancer Lett 207(2):221–227
Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D, Caers J (2011) Biological aspects of angiogenesis in multiple myeloma. Int J Hematol 94(6):505–518
Pui C-H, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2):166–178
Aricó M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T, Gadner H, Gaynon P, Horibe K, Hunger SP, Janka-Schaub G, Masera G, Nachman J, Pieters R, Schrappe M, Schmiegelow K, Valsecchi MG, Pui C-H (2005) The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29–30, 2005. Leukemia 19(7):1145–1152
Banavali SD, Goyal L, Nair R, Biswas G, Amare-Kadam P, Baisane C, Mahadik S, Gujral S, Karanth N, Arora B, Bhagwat R, Kurkure P, Parikh P (2005) A novel, efficacious therapeutic approach to patients with acute promyelocytic leukemia (APL) using differentiating agent and metronomic chemotherapy (CT). ASH Annu Meet Abstr 106(11):900
Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ (2008) Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 113(9):2504–2511
Roboz GJ, Ritchie EK, Curcio T, Samuel M, Provenzano J, Segovia J, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ (2011) Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leuk Res 35(4):522–525
Boyd D, Coleman M, Papish S, Topilow A, Kopel S, Bernhardt B, Files J, Schwartz S, Gaynor M, McDermott D (1988) COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 6(3):425–433
Hainsworth JD, Johnson DH, Frazier SR, Greco FA (1990) Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 26(7):818–821
Brugières L, Pacquement H, Le Deley M-C, Leverger G, Lutz P, Paillard C, Baruchel A, Frappaz D, Nelken B, Lamant L, Patte C (2009) Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 27(30):5056–5061
Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M (2006) High-Dose celecoxib and metronomic ‘low-dose’ cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma. Clin Cancer Res 12(17):5190–5198
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T (2008) Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 49(3):447–450
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP (2008) Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 112(10):2228–2232
Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP (2010) Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 116(11):2655–2664
Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SC (2009) Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin’s lymphoma in East Africa. J Clin Oncol 27(21):3480–3488
Zhou F, Guo L, Shi H, Lin C, Hou J (2010) Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 10(1):51–55
Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, Abonour R (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 12(1):99–106
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf H-H, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J (2007) Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 138(3):330–337
Kyriakou C, Thomson K, D’Sa S, Flory A, Hanslip J, Goldstone AH, Yong KL (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 129(6):763–770
Reece DE, Rodriguez GP, Chen C, Trudel S, Kukreti V, Mikhael J, Pantoja M, Xu W, Stewart AK (2008) Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 26(29):4777–4783
Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VHJ, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23(7):1337–1341
Coleman M, Gerstein G, Topilow A, Lebowicz J, Berhardt B, Chiarieri D, Silver RT, Pasmantier MW (1987) Advances in chemotherapy for large cell lymphoma. Semin Hematol 24(2 Suppl 1):8–20
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Praditsuktavorn, P., Ruan, J. (2014). Metronomic Chemotherapy in Hematological Malignancies. In: Bocci, G., Francia, G. (eds) Metronomic Chemotherapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43604-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-43604-2_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43603-5
Online ISBN: 978-3-662-43604-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)